Viking Therapeutics (VKTX) Stock Forecast & Price Target

Compare

7,108 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VKTX Analyst Ratings

Strong Buy

16 Buy

1 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Viking

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VKTX Stock 12 Month Forecast

Average Price Target

$95.47

▲(144.11% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $95.47 with a high forecast of $125.00 and a low forecast of $29.00. The average price target represents a 144.11% change from the last price of $39.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","48":"$48","74":"$74","100":"$100","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$95.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,48,74,100,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.08,44.76615384615384,51.45230769230769,58.13846153846154,64.82461538461538,71.51076923076923,78.19692307692307,84.88307692307693,91.56923076923077,98.25538461538461,104.94153846153846,111.62769230769231,118.31384615384616,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.08,42.494615384615386,46.90923076923077,51.32384615384615,55.738461538461536,60.153076923076924,64.56769230769231,68.98230769230769,73.39692307692307,77.81153846153846,82.22615384615384,86.64076923076922,91.05538461538461,{"y":95.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.08,37.38153846153846,36.683076923076925,35.98461538461538,35.286153846153844,34.58769230769231,33.88923076923077,33.19076923076923,32.49230769230769,31.793846153846154,31.095384615384614,30.396923076923077,29.698461538461537,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":72.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$125.00

Average Price Target$95.47

Lowest Price Target$29.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward Nash

Canaccord Genuity

$106→$107

Buy

173.59%

Upside

Reiterated

11/11/25

Analysts' Top Healthcare Picks: Viking Therapeutics (VKTX), Privia Health Group (PRVA)

Biren Amin

Piper Sandler

$71

Buy

81.54%

Upside

Reiterated

11/10/25

Piper Sandler Remains a Buy on Viking Therapeutics (VKTX)

Naz Rahman

Maxim Group

$70

Buy

78.98%

Upside

Reiterated

11/07/25

Viking Therapeutics' VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating

Andy Hsieh

William Blair

―

Buy

―

Reiterated

11/06/25

Viking Therapeutics' VK2735 Trials and Strategic Positioning Drive Buy RatingWe believe that this slower ramp-up in dose could contribute to improved tolerability owing to lower rates of gastrointestinal adverse events.

Joseph Pantginis

H.C. Wainwright

$102

Buy

160.80%

Upside

Reiterated

11/06/25

Promising Potential of Viking Therapeutics' VK2735: A Buy Rating Justified by Efficacy in Weight Loss and Metabolic HealthValuation and risks to price target achievement. We reiterate our Buy rating and $102 price target. Our valuation is based on contribution from all three clinical stage assets; VK2809, 28.2% contribution (80% chance of success); VK2735, 67.4% contribution (80% chance of success); and VK0214, 4.5% contribution (30% chance of success). Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile.

Justin Zelin

BTIG

$125

Buy

219.61%

Upside

Reiterated

10/30/25

Viking Therapeutics (VKTX) Gets a Buy from BTIGWe reiterate our Buy rating and $125 PT on VKTX.

Hardik Parikh

J.P. Morgan

$80→$75

Buy

91.77%

Upside

Reiterated

10/24/25

Viking Therapeutics price target lowered to $75 from $80 at JPMorganViking Therapeutics price target lowered to $75 from $80 at JPMorgan

Thomas Smith

Leerink Partners

$118

Buy

201.71%

Upside

Reiterated

10/23/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Joon Lee

Truist Financial

―

Buy

―

Reiterated

10/23/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Annabel Samimy

Stifel Nicolaus

$95

Buy

142.90%

Upside

Reiterated

10/23/25

Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus

Steven Seedhouse

Cantor Fitzgerald

$104→$105

Buy

168.47%

Upside

Reiterated

10/23/25

Viking Therapeutics offered 'transformative' Q3 update, says Cantor FitzgeraldViking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald

Michael Ulz

Morgan Stanley

$98→$102

Buy

160.80%

Upside

Reiterated

10/23/25

Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking TherapeuticsWe are encouraged by swift execution across programs; Reiterate Overweight.

Jay Olson

Oppenheimer

$100

Buy

155.69%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT), BioLife Solutions (NASDAQ: BLFS) and Viking Therapeutics (NASDAQ: VKTX)

David Lebowitz

Citi

$38→$29

Hold

-25.85%

Downside

Reiterated

08/20/25

Viking Therapeutics (VKTX) Gets a Hold from Citi

Yale Jen

Laidlaw

$110

Buy

181.26%

Upside

Reiterated

08/20/25

Laidlaw Keeps Their Buy Rating on Viking Therapeutics (VKTX)Laidlaw analyst Yale Jen reiterated a Buy rating and $110.00 price target on Viking Therapeutic (NASDAQ: VKTX).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Nash

Canaccord Genuity

$106→$107

Buy

173.59%

Upside

Reiterated

11/11/25

Analysts' Top Healthcare Picks: Viking Therapeutics (VKTX), Privia Health Group (PRVA)

Biren Amin

Piper Sandler

$71

Buy

81.54%

Upside

Reiterated

11/10/25

Piper Sandler Remains a Buy on Viking Therapeutics (VKTX)

Naz Rahman

Maxim Group

$70

Buy

78.98%

Upside

Reiterated

11/07/25

Viking Therapeutics' VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating

Andy Hsieh

William Blair

―

Buy

―

Reiterated

11/06/25

Joseph Pantginis

H.C. Wainwright

$102

Buy

160.80%

Upside

Reiterated

11/06/25

Justin Zelin

BTIG

$125

Buy

219.61%

Upside

Reiterated

10/30/25

Viking Therapeutics (VKTX) Gets a Buy from BTIGWe reiterate our Buy rating and $125 PT on VKTX.

Hardik Parikh

J.P. Morgan

$80→$75

Buy

91.77%

Upside

Reiterated

10/24/25

Viking Therapeutics price target lowered to $75 from $80 at JPMorganViking Therapeutics price target lowered to $75 from $80 at JPMorgan

Thomas Smith

Leerink Partners

$118

Buy

201.71%

Upside

Reiterated

10/23/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Joon Lee

Truist Financial

―

Buy

―

Reiterated

10/23/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Annabel Samimy

Stifel Nicolaus

$95

Buy

142.90%

Upside

Reiterated

10/23/25

Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus

Steven Seedhouse

Cantor Fitzgerald

$104→$105

Buy

168.47%

Upside

Reiterated

10/23/25

Viking Therapeutics offered 'transformative' Q3 update, says Cantor FitzgeraldViking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald

Michael Ulz

Morgan Stanley

$98→$102

Buy

160.80%

Upside

Reiterated

10/23/25

Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking TherapeuticsWe are encouraged by swift execution across programs; Reiterate Overweight.

Jay Olson

Oppenheimer

$100

Buy

155.69%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT), BioLife Solutions (NASDAQ: BLFS) and Viking Therapeutics (NASDAQ: VKTX)

David Lebowitz

Citi

$38→$29

Hold

-25.85%

Downside

Reiterated

08/20/25

Viking Therapeutics (VKTX) Gets a Hold from Citi

Yale Jen

Laidlaw

$110

Buy

181.26%

Upside

Reiterated

08/20/25

Laidlaw Keeps Their Buy Rating on Viking Therapeutics (VKTX)Laidlaw analyst Yale Jen reiterated a Buy rating and $110.00 price target on Viking Therapeutic (NASDAQ: VKTX).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viking Therapeutics

1 Month

xxx

Success Rate

14/22 ratings generated profit

Average Return

+13.02%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +13.02% per trade.

3 Months

xxx

Success Rate

15/24 ratings generated profit

Average Return

+21.52%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +21.52% per trade.

1 Year

Naz RahmanMaxim Group

Success Rate

18/24 ratings generated profit

Average Return

+140.01%

reiterated a buy rating 12 days ago

Copying Naz Rahman's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +140.01% per trade.

2 Years

xxx

Success Rate

19/24 ratings generated profit

Average Return

+211.06%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 79.17% of your transactions generating a profit, with an average return of +211.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VKTX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VKTX has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VKTX average Analyst price target in the past 3 months is 95.47.

Each month's total comprises the sum of three months' worth of ratings.

VKTX Financial Forecast

VKTX Earnings Forecast

Next quarter’s earnings estimate for VKTX is -$0.89 with a range of -$1.06 to -$0.79. The previous quarter’s EPS was -$0.81. VKTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year VKTX has Performed in-line its overall industry.

No data currently available

VKTX Sales Forecast

Next quarter’s sales forecast for VKTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VKTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year VKTX has Performed in-line its overall industry.

VKTX Stock Forecast FAQ

What is VKTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Viking Therapeutics’s 12-month average price target is 95.47.

What is VKTX’s upside potential, based on the analysts’ average price target?

Viking Therapeutics has 144.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VKTX a Buy, Sell or Hold?

Viking Therapeutics has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.

What is Viking Therapeutics’s price target?

The average price target for Viking Therapeutics is 95.47. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $29.00. The average price target represents 144.11% Increase from the current price of $39.11.

What do analysts say about Viking Therapeutics?

Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of VKTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Viking Therapeutics (VKTX) Stock Forecast & Price Target

VKTX Analyst Ratings

VKTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viking Therapeutics

VKTX Analyst Recommendation Trends

VKTX Financial Forecast

VKTX Earnings Forecast

VKTX Sales Forecast

VKTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts